AstraZeneca stock opens new Massachusetts research center
Published on 10/05/2026 at 22:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca stock (ISIN GB0009895292) was trading at GBp 11,889.92 on the London Stock Exchange on October 5, 2026, with a 0.17 percent gain for the session. The company opened a new global strategic research and development center in Kendall Square, Cambridge, Massachusetts, according to Business Wire on October 5, 2026.
New center expands research capacity
The Kendall Square facility extends AstraZeneca's existing presence in Cambridge and Boston and places its scientists inside a major US life sciences cluster. The opening gives the company a fresh operational focus as it continues building medicines across oncology, rare disease and biopharmaceuticals.
The event follows AstraZeneca's completed USD 2 billion equity investment in Summit Therapeutics, which supports development of the cancer drug ivonescimab in combination with antibody drug conjugates. That transaction and the new research center both connect the companys capital spending with its oncology pipeline.
Q2 revenue reached USD 15.38 billion
AstraZeneca reported Q2 2026 revenue of USD 15.38 billion, up 6.4 percent from the prior-year quarter, while quarterly EPS reached USD 2.63 versus a USD 2.50 consensus estimate, according to MarketBeat. The figures show the tension in the current setup: revenue growth remains positive, while the share price is still well below its annual peak.
The LSE quote's October 5 range was GBp 11,864.00 to GBp 11,944.00, with volume of 229,600 shares. Its 52-week range was GBp 10,524.00 to GBp 15,730.00, placing the current price 24.4 percent below the high and 13.0 percent above the low.
Analysts keep a Moderate Buy view
MarketBeat reported on October 4, 2026, that seven analysts held a Moderate Buy consensus, including six Buy ratings and one Hold rating. The average 12-month price target was GBP 150, with targets ranging from GBP 117 to GBP 178.
A separate October 5 analysis cited 28 analysts and a consensus target of 15,972p, while Deutsche Bank had reiterated a Hold rating with a 11,700p target on September 29, according to Yahoo Finance. The spread between those views highlights how pipeline execution remains central to the valuation discussion.
Investor events are scheduled
AstraZeneca's investor-relations calendar lists management events at ASBMR on October 12, 2026, and ESMO on October 26, 2026, according to the company's investor-relations page. These dates give investors two upcoming checkpoints for pipeline updates after the Kendall Square opening.
Stock remains below its yearly high
AstraZeneca stock was last trading at GBp 11,889.92 on the London Stock Exchange on October 5, 2026. The 24.4 percent gap to the 52-week high keeps the market's attention on earnings delivery and the company's expanding oncology pipeline.
AstraZeneca stock facts
- Company: AstraZeneca PLC
- ISIN: GB0009895292
- Ticker: AZN
- Trading venue: London Stock Exchange
- Price (as of October 5, 2026): GBp 11,889.92
- 52-week range: GBp 10,524.00-15,730.00
- Sector / Industry: Healthcare / Pharmaceuticals
- Index membership: FTSE 100
Upcoming dates for AstraZeneca stock
- October 12, 2026: ASBMR management event
- October 26, 2026: ESMO management event
